ORCID Profile
0000-0002-7372-1154
Current Organisations
Princess Alexandra Hospital
,
University of Queensland School of Pharmacy
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Wiley
Date: 30-10-2012
DOI: 10.1111/AJCO.12030
Publisher: Wiley
Date: 02-2022
DOI: 10.1002/JPPR.1768
Abstract: The aim of this brief report was to retrospectively compare the severity and incidence of hypersensitivity reactions (HSRs) in patients who received ranitidine and patients who did not receive ranitidine, as part of their pre‐medication prior to paclitaxel. Data was collected for patients receiving paclitaxel‐containing protocols for breast, head and neck, or lung cancers in 2019 and 2020. The data included the pre‐medications administered prior to each paclitaxel dose, the total doses received and whether a HSR event occurred along with its severity. Eighty patients were reviewed receiving a total of 512 paclitaxel doses with 17 HSRs identified in 15 patients. Of the 241 doses in the ranitidine group, 11 HSRs were recorded for nine patients, compared to the 271 doses in the non‐ranitidine group where six HSRs were recorded for six patients. Most of the 512 chemotherapy doses were preceded by dexamethasone (100%) and loratadine (99.6%). Our results show that the incidence of paclitaxel‐related HSRs was not lowered with the addition of ranitidine to dexamethasone and loratadine. Future studies are warranted exploring the use of any H2‐antagonist as part of the pre‐medication regimen with paclitaxel‐containing protocols and their clinical relevance in preventing or minimising HSR incidence and severity.
Publisher: Therapeutic Guidelines Limited
Date: 10-2015
DOI: 10.18773/AUSTPRESCR.2015.060
Abstract: Oral targeted therapies are increasingly being used to treat cancer. They work by interfering with specific molecules or pathways involved in tumour growth. It is essential that health professionals managing patients taking these drugs have appropriate training and skills. They should be aware of potential adverse effects and drug interactions, and be able to manage toxicities when they occur. Despite the selectivity of these targeted therapies, they still have serious adverse effects including skin reactions, diarrhoea and altered organ function.
Publisher: Informa UK Limited
Date: 12-10-2016
Publisher: Wiley
Date: 30-01-2022
DOI: 10.1111/AJCO.13656
Abstract: Nonadherence to oral chemotherapy (OC) can lead to health complications, including premature death. Mobile phones are increasingly used to deliver medication adherence interventions. However, there is limited evidence about mobile phone-based interventions to increase adherence to OC, specifically. This study explores the proof-of-concept of a smartphone program to support adherence to OC in people with cancer. This was a 10-week, nonrandomized, multisite trial. The outcomes assessed were acceptability, satisfaction with the intervention, adherence to OC, knowledge about OC, and side-effects presence and severity. The program consisted of short message service (SMS) reminders to take OC, as well as information about OC, including the management of side-effects. Twenty-two participants (17-74 y/o, median age 60 y/o) were recruited at six hospitals. The s le included 10 different cancer diagnoses (predominance of breast cancer) and 11 OC medications. Acceptability of the intervention was high, with 95% of the enrolled participants completing postintervention measures, and 81% reporting high satisfaction with the program. The intervention was found to have no effect on supporting adherence to OC (assessed by self-report and medication event monitoring system) in this s le. An increase in knowledge about OC was observed at postintervention (p = 0.010). This study demonstrated proof-of-concept of the smartphone program and highlighted the need for intervention and trial design-related refinements. Future work should evaluate the effect of the program on adherence to OC with nonadherent patients.
Publisher: Wiley
Date: 03-2016
DOI: 10.1002/JPPR.1199
Publisher: Wiley
Date: 14-04-2020
DOI: 10.1111/AJCO.13337
Publisher: Wiley
Date: 06-2008
Publisher: Wiley
Date: 31-08-2010
DOI: 10.1111/J.1743-7563.2010.01321.X
Abstract: The issue of medication safety is highly significant when anti-cancer therapy is used as a treatment modality due to the high potential for harm from these agents and the disease context in which they are being used. These guidelines provide recommendations on the safe prescribing, dispensing and administration of chemotherapy and related agents used in the treatment of cancer. The guidelines represent a multidisciplinary collaboration to standardise the complex process of providing chemotherapy for cancer and to enhance patient safety. These are consensus guidelines based on the best available evidence and expert opinion of professionals working in cancer care. The aim of these guidelines is to assist in the prevention of medication errors and to improve patient safety with respect to the treatment of cancer. This guidance is intended for a multi-disciplinary audience and will have most relevance for medical, nursing and pharmacy staff involved in the complex processes of delivering chemotherapy and associated treatment. The scope of the guidelines includes all patients and age groups receiving chemotherapy and targeted therapy for the treatment of cancer and cancer therapy administered by any route in both the hospital and home setting. These guidelines should be seen as point of reference for practitioners providing cancer chemotherapy services.
Publisher: American Society of Clinical Oncology (ASCO)
Date: 20-05-2010
Publisher: Wiley
Date: 31-08-2010
DOI: 10.1111/J.1743-7563.2010.01313.X
Abstract: The issue of medication safety is highly significant when anti-cancer therapy is used due to the high potential for harm from these agents and the disease context in which they are being used. This article reports on the development of multidisciplinary consensus guidelines for the safe prescribing, dispensing and administration of cancer chemotherapy undertaken by a working group of the Clinical Oncological Society of Australia (COSA). A working group of pharmacists, nurses and medical oncologists was convened from the COSA membership. A draft set of guidelines was proposed and circulated to the COSA council and the wider membership of COSA for comment. The final version of the guidelines was then distributed to 25 key stakeholders in Australia for feedback and endorsement. An initial draft was developed based on existing standards, evidence from the literature and consensus opinion of the group. It was agreed that published case studies would be used as evidence for a particular statement where related processes had resulted in patient harm. The group defined 13 areas where a guidance statement was applicable to all professional disciplines and three in idual sections based on the processes and the professionals involved in the provision of cancer therapy. The guidelines development represents a multidisciplinary collaboration to standardize the complex process of providing chemotherapy for cancer and to enhance patient safety. These are consensus guidelines based on the best available evidence and expert opinion of professionals working in cancer care. They should be seen as a point of reference for practitioners providing chemotherapy services.
Publisher: Therapeutic Guidelines Limited
Date: 02-2013
Publisher: Springer Science and Business Media LLC
Date: 04-2014
DOI: 10.1038/CLPT.2014.3
Publisher: Springer Science and Business Media LLC
Date: 24-07-2013
DOI: 10.1038/SREP02276
Publisher: Wiley
Date: 06-2007
Publisher: The Electrochemical Society
Date: 12-08-2014
Abstract: We show that geometric shielding of the reactive flux in chemical vapor deposition by tall neighboring structures obtained by deep substrate patterning, along with short surface diffusion lengths, can provide nearly space filling arrays of high-quality epitaxial crystals despite large mismatches of lattice parameters and thermal expansion coefficients. The density of extended defects is strongly reduced by the method, and wafer bowing and crack formation largely inhibited. The concept is shown to be valid for SiGe/Si heterostructures ranging from pure Si to pure Ge both on Si(001) and Si(111) substrates. Here, dislocations are efficiently eliminated from three-dimensional faceted crystals with high-aspect ratios on top of micron-sized Si pillars. The application to 3C-SiC/Si(001) ridges, characterized by a lattice mismatch of nearly 20%, provides significantly lower stacking fault densities compared with layers grown on planar substrates.
Location: United Kingdom of Great Britain and Northern Ireland
Location: United Kingdom of Great Britain and Northern Ireland
Location: United Kingdom of Great Britain and Northern Ireland
Location: United Kingdom of Great Britain and Northern Ireland
Location: United Kingdom of Great Britain and Northern Ireland
No related grants have been discovered for Christine Carrington.